Dr. Mahtani on Side Effects of Ovarian Suppression in Breast Cancer

Video

In Partnership With:

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses side effects of ovarian suppression in patients with breast cancer.

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses side effects of ovarian suppression in patients with breast cancer.

Updated data from the TEXT and SOFT clinical trials in premenopausal women with hormone-receptor positive breast cancer showed that there is a benefit to ovarian function suppression. Although, investigators observed that absolute benefits were greater in patients who had higher risk of disease.

Generally, ovarian function suppression is associated with more side effects for most pre-menopausal patients, says Mahtani. Additionally, the use of an aromatase inhibitor (AI) as opposed to tamoxifen may lead to join discomfort, osteoporosis, and issues with libido. Mahtani says that when ovarian function suppression is used with an AI, side effects can be more prevalent, so clinicians should be sure to only use that option in the patients who will derive the most benefit.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD